Ghada Ismail Zaki

Dr. Ghada Ismail Zaki

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

13 May 2025 in Fishes
Verified
Journal Article
Open access
PDF file
EBEmily Burch
Emily Burch
MHMohamed Ali Hussein
Mohamed Ali Hussein
MHManar A. Zaki Hussein
Manar A. Zaki Hussein
LKLereen T. Kamal
Lereen T. Kamal
GZGhada Ismail Zaki
Ghada Ismail Zaki
AAAnwar Abdelnaser
Anwar Abdelnaser
Aquaculture has been rapidly growing during the past decade to accommodate the increasing need for seafood as a vital source of nutrients for human beings. The nutritional benefits of incorporating fish into one’s diet are paramount in promoting overall health, bolstering immunity and warding off diseases. Nonetheless, farm-raised aquatic species are frequently subjected to elevated contamination levels due to pesticides, antibiotics, and heavy metals in the marine environment. Pesticides affect fish differently based on species, class, dosage, and exposure duration. They can induce histological damage or neurobehavioral changes by inhibiting acetylcholinesterase production. This can promote liver dysfunction, metabolism deregulation, oxidative stress, and hematological imbalances, impair immune responses, and adversely affect fish reproduction. Furthermore, pesticides negatively affect the nutritional composition of fish by reducing the total protein levels in muscle, liver, gills, and kidney tissues. They disrupt lipid metabolism, resulting in lipid accumulation in the liver and a decrease in polyunsaturated fatty acids. Additionally, pesticides interfere with metabolism by altering carbohydrate levels in the gills, muscles, and kidneys while decreasing glycogen storage in the liver. Pesticide exposure has been linked to severe health impacts in humans, such as non-communicable diseases, reproductive issues, cognitive dysfunction, and cancer. The current review comprehensively emphasizes the harmful effects of pesticides on fish and human health, urging the establishment of environmental monitoring programs and biomonitoring studies. It accentuates the need for risk assessment models to evaluate pesticide impacts on marine ecosystems and advocates for stricter safety standards and lower pesticide residue limits in aquaculture products.

27 October 2025 in Therapeutic Innovation & Regulatory Science
Verified
Journal Article
Open access
PDF file
MOMercy Owusu-Asante
Mercy Owusu-Asante
DDDelese Mimi Darko
Delese Mimi Darko
BSBoitumelo Semete-Makokotieia
Boitumelo Semete-Makokotieia
CAChristianah Mojisola Adeyeye
Christianah Mojisola Adeyeye
AFAdam Mitangu Fimbo
Adam Mitangu Fimbo
SSSam Salek
Sam Salek
Background: The World Health Organization (WHO) developed the WHO Global Benchmarking Tool (GBT) to assess and benchmark the drug regulatory systems and practices in national medicines regulatory authorities (NMRAs). The objective of the study was to identify strengths and opportunities for improvement by comparing the regulatory performance of the NMRAs in Egypt, Ghana, Nigeria, South Africa, Tanzania and Zimbabwe, all which have attained maturity level 3 status for medicines and /or vaccines, in order to enhance regulatory review processes and patients’ access to medicines and/or vaccines. Methods: The NMRAs selected for the study completed a questionnaire that collected data and metrics that facilitated comparative studies among the NMRAs. Results: The comparative study showed that similarities among these authorities also translated into their strengths. The study revealed that the human resource capacity in African NMRAs is inadequate to fully execute regulatory mandates. Review process map comparison revealed the important observation that these NMRAs conducted labelling review early in the review process rather than in the latter stages of the process. Conclusion: The study has identified the regulatory best practices that led to the NMRAs achieving WHO GBT maturity level 3. The African Medicines Agency should engage these maturity level-3 NMRAs to explore ways of benefiting from their experience and resources. It is hoped that through such engagement, the NMRAs will be encouraged to further develop their capacity to help the AMA to achieve its mandate. Additionally, by addressing the identified gaps and recommendations in the study these NMRAs can achieve WHO GBT maturity level 4 whilst NMRAs who have not yet reached GBT maturity level 3 can also benefit from this study in order to reach higher maturity levels.

8 October 2026 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
GZGhada Ismail Zaki
Ghada Ismail Zaki
SSSam Salek
Sam Salek
SWStuart Walker
Stuart Walker
SCSungsoo Chun
Sungsoo Chun
Introduction: Good Review Practices (GRevPs) are considered of value for regulatory system strengthening that support timely, consistent, transparent, and high-quality regulatory reviews. It is therefore important that GRevPs are continuously updated and monitored to improve the review process. This study is the first assessment of GRevPs within the Egyptian Drug Authority (EDA) and provides a baseline for future monitoring and improvement. Methods: A cross-sectional study was conducted among Marketing Authorisation (MA) assessors within the EDA using a semi-structured questionnaire. It comprised two sections: the validated Good Review Practices (GRevPs) questionnaire developed by the Centre for Innovation in Regulatory Science (CIRS), which assessed knowledge, attitudes, practices and barriers to GRevPs adoption; and a study-specific section assessing the perceived importance and implementation of review-quality activities. Descriptive statistics summarised the data, while a gap analysis using mean differences and an Importance-Performance Analysis (IPA) matrix identified priority areas for improvement. Open-ended responses were analysed using conventional content analysis. Results: Fifty-five of the 80 assessors approached completed the questionnaire (69%). Within the MA departments, respondents reported comparable levels of full and partial adoption of GRevPs (44% and 53%, respectively). Assessors demonstrated a good understanding of GRevPs and identified efficiency, consistency, reduced duplication, and error minimisation as key benefits. Gap analysis showed that review-quality activities were recognised as important, with positive practices and attitudes toward GRevPs. However, areas requiring further improvement included continuous, practice-oriented training; proactive communication with applicants; adherence to timelines; cross-team coordination; consistent recording and updating of review information; and mechanisms for acting on applicant feedback. High workload, limited staffing capacity, time pressure, and communication challenges were identified as the main barriers to implementation. Discussion: These findings indicate that EDA has established a strong foundation for implementing GRevPs, supported by documented procedures, review tools, and assessors’ understanding. However, greater attention is needed to ensure consistent implementation, monitoring, and continuous improvement of GRevPs, particularly through ongoing practical training, digitalisation, external tracking mechanisms, and adequate resource allocation. As the Egyptian Drug Authority (EDA) progresses towards Maturity Level 4 and WHO-Listed Authority aspirations, understanding how GRevPs are perceived and implemented in practice becomes increasingly important.

15 June 2026 in Frontiers in Nutrition
Verified
Journal Article
Open access
PDF file
GZGhada Ismail Zaki
Ghada Ismail Zaki
WAWajeeh Al-Dekhail
Wajeeh Al-Dekhail
MMMohamed Mezied
Mohamed Mezied
SSSanaa Shaaban
Sanaa Shaaban
YGYasmin El Gendy
Yasmin El Gendy
AAAhmed Abdelmawla
Ahmed Abdelmawla
Introduction: Disease-related malnutrition is a significant yet underappreciated burden among hospitalized children, particularly in the Middle East, where data on prevalence and economic effects are few. DRM perpetuates a vicious cycle in which diseases lead to malnutrition, and malnutrition in turn worsens disease outcomes, prolongs recovery, and raises healthcare expenses. Although nutritional treatments are clinically useful in DRM management, information on their economic effects is sparse. Objective: To estimate the budget impact and potential cost savings of introducing energy-and nutrient-dense formulas (ENDFs) for hospitalized pediatric DRM patients aged 0–5 years across public and private sectors in Egypt, Saudi Arabia, Kuwait, and the United Arab Emirates. Methods: An Excel-based cost calculator model compared standard nutritional formulas to ENDFs over a one-year horizon from a healthcare payer’s perspective across both public and private sectors. The model estimated annual direct medical costs, incorporating population inputs, formulas, and hospitalization costs, as well as hospital length of stay (LOS), informed by expert consultations. One-way sensitivity analyses (±20%) were conducted to assess the model’s robustness. Further, Scenario analyses using alternative uptake assumptions (25, 50, and 75%) were also conducted to improve the practical relevance of the model. Results: The use of ENDFs was linked to consistent reductions in LOS (19–50%) and significant cost savings (15–50%), mainly driven by lower hospitalization expenses, which made up over 95% of total costs. Sensitivity analysis showed that prevalence, LOS reduction percentage, and baseline LOS were the main cost drivers, in line with previous economic models. Conclusion: The findings demonstrate the clinical and economic value of ENDFs in managing pediatric DRM, through reduced hospital length of stay and associated costs, supporting their broader adoption.